iShares Health Innovation Active ETF
iShares Health Innovation Active ETF reported 58 holdings worth US$11.2M as of Jul 31, 2026 (Form N-PORT)
As of Jul 31, 2026 · Filed Sep 25, 2026
iShares Health Innovation Active ETF reported 58 holdings worth US$11.2M as of Jul 31, 2026. Largest: Merck & Company, Inc., Gilead Sciences, Inc. and Johnson & Johnson. Filed Sep 25, 2026 (Form N-PORT).
- Holdings
- 58
- Value as reported
- US$11.2M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Merck & Company, Inc. | 5,064 | US$659K | 5.9% |
| Gilead Sciences, Inc. | 4,165 | US$542K | 4.9% |
| Johnson & Johnson | 1,955 | US$501K | 4.5% |
| Edwards Lifesciences Corporation | 5,726 | US$493K | 4.4% |
| Thermo Fisher Scientific Inc | 812 | US$466K | 4.2% |
| Charles River Laboratories International, Inc. | 1,783 | US$415K | 3.7% |
| Danaher Corporation | 2,077 | US$405K | 3.6% |
| Biogen Inc. | 1,935 | US$393K | 3.5% |
| Waters Corporation | 1,035 | US$391K | 3.5% |
| Mettler-toledo International, Inc. | 274 | US$388K | 3.5% |
| Abbvie Inc. | 1,528 | US$383K | 3.4% |
| Vertex Pharmaceuticals Incorporated | 690 | US$329K | 3.0% |
| Moderna, Inc. | 5,948 | US$326K | 2.9% |
| Dexcom, Inc. | 3,493 | US$291K | 2.6% |
| Amgen Inc. | 722 | US$278K | 2.5% |
| Bio-techne Corp | 3,805 | US$274K | 2.5% |
| Illumina, Inc. | 1,309 | US$268K | 2.4% |
| Novartis Ag | 1,579 | US$247K | 2.2% |
| Incyte Corporation | 1,981 | US$237K | 2.1% |
| Roche Holding Ltd | 540 | US$236K | 2.1% |
| Iqvia Holdings, Inc. | 929 | US$218K | 2.0% |
| Argenx Se | 250 | US$213K | 1.9% |
| Cytokinetics, Incorporated | 2,600 | US$201K | 1.8% |
| Neurocrine Biosciences, Inc. | 1,145 | US$191K | 1.7% |
| Abbott Laboratories | 1,797 | US$190K | 1.7% |
| Guardant Health, Inc. | 1,050 | US$170K | 1.5% |
| Roivant Sciences Ltd. | 4,654 | US$158K | 1.4% |
| Astrazeneca Plc | 875 | US$148K | 1.3% |
| Bristol-myers Squibb Company | 2,169 | US$142K | 1.3% |
| Axsome Therapeutics, Inc. | 649 | US$141K | 1.3% |
| Biomarin Pharmaceutical Inc. | 2,280 | US$137K | 1.2% |
| Revolution Medicines, Inc. | 723 | US$136K | 1.2% |
| Wuxi Biologics (cayman) Inc. | 26,500 | US$131K | 1.2% |
| Bruker Corporation | 1,844 | US$116K | 1.0% |
| Protagonist Therapeutics, Inc. | 780 | US$107K | 0.96% |
| Ucb S.a. | 333 | US$85,476 | 0.77% |
| Alkermes Plc | 1,712 | US$83,871 | 0.75% |
| Apogee Therapeutics, Inc. | 576 | US$77,236 | 0.69% |
| Arcus Biosciences, Inc. | 2,566 | US$72,336 | 0.65% |
| Dianthus Therapeutics, Inc. | 651 | US$69,605 | 0.62% |
| Mbx Biosciences, Inc. | 993 | US$65,468 | 0.59% |
| Cogent Biosciences, Inc. | 1,632 | US$63,534 | 0.57% |
| Insmed Incorporated | 493 | US$48,610 | 0.44% |
| Erasca, Inc. | 2,375 | US$43,106 | 0.39% |
| Avalo Therapeutics, Inc. | 781 | US$14,253 | 0.13% |
| Halozyme Therapeutics, Inc. | 155 | US$12,794 | 0.11% |
| Sagimet Biosciences Inc. - Series A | 1,688 | US$12,002 | 0.11% |
| Eikon Therapeutics, Inc. | 1,253 | US$11,540 | 0.10% |
| Ultragenyx Pharmaceutical Inc. | 460 | US$11,459 | 0.10% |
| Summit Therapeutics Inc. | 636 | US$8,281 | 0.07% |
| Teva Pharmaceutical Industries Limited | 0 | US$0 | 0.00% |
| Pfizer, Inc. | 0 | US$0 | 0.00% |
| Medline Inc. | 0 | US$0 | 0.00% |
| Idexx Laboratories, Inc. | 0 | US$0 | 0.00% |
| Alcon Ag | 0 | US$0 | 0.00% |
| Boston Scientific Corporation | 0 | US$0 | 0.00% |
| Intuitive Surgical, Inc. | 0 | US$0 | 0.00% |
| Gsk Plc | 0 | US$0 | 0.00% |
Source
View original at SEC
Related